🇺🇸 FDA
Pipeline program

Oxybutinyn Vaginal Ring 4mg

DR-OXY-302

Phase 3 small_molecule completed

Quick answer

Oxybutinyn Vaginal Ring 4mg for Overactive Bladder is a Phase 3 program (small_molecule) at Teva Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Teva Pharma GmbH
Indication
Overactive Bladder
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials